PZ0170
Torcetrapib
≥98% (HPLC)
别名:
(2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester, CP-529,414, CP-529414
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H25F9N2O4
化学文摘社编号:
分子量:
600.47
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
SMILES string
CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c3cc(ccc13)C(F)(F)F
InChI key
CMSGWTNRGKRWGS-NQIIRXRSSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D >-70°
color
white
solubility
DMSO: >5 mg/mL
storage temp.
2-8°C
Quality Level
Application
Torcetrapib has been used as a reference standard in the medium chain-lipid based formulations.
Biochem/physiol Actions
Cholesteryl ester transfer protein (CETP) inhibitor.
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Shengjun Fan et al.
BMC systems biology, 6, 152-152 (2012-12-12)
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor which raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol level, has been documented to increase mortality and cardiac events associated with adverse effects. However, it is still unclear the
Philip J Barter et al.
Journal of lipid research, 53(11), 2436-2442 (2012-09-04)
Development of the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib, was halted after the ILLUMINATE trial revealed an increase in both all-cause mortality (ACM) and major cardiovascular events (MCVEs) associated with its use. We now report that the harm caused
Anatol Kontush et al.
Nature clinical practice. Cardiovascular medicine, 5(6), 329-336 (2008-04-24)
Subnormal levels of HDL cholesterol constitute a major cardiovascular risk factor. Inhibitors of cholesteryl ester transfer protein (CETP) are presently the most potent HDL-raising agents. Torcetrapib was the first CETP inhibitor to enter a large-scale, prospective, placebo-controlled interventional trial, which
Bernd Hewing et al.
Current opinion in lipidology, 23(4), 372-376 (2012-04-21)
Raising HDL cholesterol (HDL-C) has become an attractive therapeutic target to lower cardiovascular risk in addition to statins. Inhibition of the cholesteryl ester transfer protein (CETP), which mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing particles, leads
Aldosterone, sodium, and hypertension: lessons from torcetrapib?
John W Funder
Hypertension (Dallas, Tex. : 1979), 55(2), 221-223 (2010-01-06)
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持